Potential in retina treatment offered through stem cell research

Article

A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight.

A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight. This could lead to a potential treatment for retinal diseases that affect around 3000 children in the UK.

Researchers from the UCL Institute of Child Health and UCL Institute of Ophthalmology as well as members of the UCL Centre for Stem Cells and Regenerative Medicine have successfully implanted cells from healthy mice into those with an inherited form of childhood blindness called Leber Congenital Amaurosis (LCA). The implanted cells, which release a gene, Crx, needed to make healthy cone and rod photoreceptors, integrated with the retina to become new cone photoreceptors. This is the first time this has been achieved. However, more studies are required to show if this method could restore sight.

"We have shown for the first time that it is possible to transplant new cone photoreceptors into the mature retina. The newly-developed cones looked as good as new," asserted Dr Jane Sowden, UCL Institute of Child Health, who led the study. "This is an important step forward as cone photoreceptors are essential for reading and colour vision and loss of this type of cell has the biggest impact on sight."

This study is available in Human Molecular Genetics.

For further information on stem cell technology read the upcoming October issue of Ophthalmology Times Europe for "A primer on the use of stem cells in ophthalmology" by Irving Arons.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.